Is There A Point To Subgroup Analyses Of STABILITY?
This article was originally published in Pharmaceutical Approvals Monthly
Co-chair of the failed study says secondary endpoints adding revascularization and unstable angina to the hard MACE primary endpoint show “hypothesis-generating” findings, but discussant Kastelein questions the prospects for any more trials to test those hypotheses.
You may also be interested in...
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Acer repurposes drugs with available data (like a 40-year-old European antihypertensive) into rare disease treatments (like Edsivo for vascular Ehlers-Danlos syndrome), but approval remains elusive, with a CRL for ACER-001 just as Edsivo is poised to enter a new clinical trial, armed with a new breakthrough designation. The Pink Sheet delves into regulatory history and strategy with CEO Chris Schelling.